Efficacy of short-course ceftriaxone therapy for Borrelia burgdorferi infection in C3H mice

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 1, 2002, Pages 132-134

  Pavia, C ^a   Inchiosa M A , Jr ^a   Wormser, G P ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTRIAXONE; CORTISONE ACETATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC THERAPY; ARTICLE; BORRELIA BURGDORFERI; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; FEMALE; IMMUNOSUPPRESSIVE TREATMENT; LYME DISEASE; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; SHORT COURSE THERAPY;

ANIMALS; BORRELIA BURGDORFERI; CEFTRIAXONE; CEPHALOSPORINS; DISEASE MODELS, ANIMAL; FEMALE; LYME DISEASE; MICE; MICE, INBRED C3H; TREATMENT OUTCOME;

EID: 0036136839     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.1.132-134.2002     Document Type: Article

References (22)

1. 2 bonded phase column
2. In vitro susceptibility of thirty Borrelia strains from various sources against eight antimicrobial chemotherapeutics
3. Efficacy of SCH27899 in an animal model of Legionnaires' disease using immunocompromised A/J mice
4. Borrelia recurrentis infection: Single-dose antibiotic regimens and management of Jarisch-Herxheimer reaction
5. Therapy of pulmonary nocardiosis in immunocompromised mice
6. In vitro and in vivo susceptibility of the Lyme disease spirochete, Borrelia burgdorferi, to four antimicrobial agents
7. In vivo activities of ceftriaxone and vancomycin against Borrelia spp. in the mouse brain and other sites
8. Effectiveness of antimicrobial treatment against Borrelia burgdorferi infection in mice
9. In vitro and in vivo susceptibility of Borrelia burgdorferi
10. Failure of treatment with cephalexin for Lyme disease
11. Pharmacokinetic profile of ceftriaxone in man
12. Activity of sera from patients with Lyme disease against Borrelia burgdorferi
13. Efficacy of an everinomycin (SCH 27899) in vitro and in an animal model of Lyme disease
14. Status of Borrelia burgdorferi infection after antibiotic treatment and effects of corticosteroids: An experimental study
15. Comparative study of the effects of four cephalosporins against Escherichia coli in vitro and in vivo
16. In vivo activity and pharmacokinetics of ziracin (SCH 27899), a new long-acting everinomycin antibiotic, in a murine model of penicillin-susceptible or penicillin-resistant pneumococcal pneumonia
17. Impact of genotypic variation of Borrelia burgdorferi sensu stricto on kinetics of dissemination and severity of disease in C3H/HeJ mice
18. A randomized trial of ceftriaxone versus oral penicillin for the treatment of early European Lyme borreliosis
19. Practice guidelines for the treatment of Lyme disease
20. Lyme disease: Insights into the use of antimicrobials for prevention and treatment in the context of experience with other spirochetal infections
21. Duration of therapy for Lyme borreliosis
22. Reactivation of Chlamydia trachomatis lung infection in mice by cortisone